Our results tend to align with these aforementioned studies in that FOXP3 + OSCCs were associated with lower T-stage, absence of lymph node metastasis, and early-stage disease (Table 3) and thus a trend toward more favorable survival outcomes (p = 0.05, Fig. 5). This evidence concerns the gene FOXP3 and metastatic malignant neoplasm in the lymph nodes.